학술논문
Atrial fibrillation in cancer, anticancer therapies, and underlying mechanisms
Document Type
Review Article
Author
Source
In Journal of Molecular and Cellular Cardiology September 2024 194:118-132
Subject
Language
ISSN
0022-2828
Abstract
Highlights •Atrial Fibrillation (AF) is prevalent among active cancer patients and survivors.•Several classes of anticancer drug therapies also increase AF risk.•Preexisting and cancer-related cardiac remodeling contributes to AF development.•Oxidative stress, inflammation, and ionic alterations have been documented.•Emerging data suggests a role for SGLT2i in management of anticancer-induced AF.